Syed Pervaiz, MD
Internal Medicine · Las Vegas, NVNPI 1326079096
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 47.8% of the total. Reporting peaked in 2021 at $1,574 and has fallen 88.0% since, to $189 in 2025.
Across 65 payments — averaging $39.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$320
- AstraZeneca$318
- Amarin Pharma, Inc.$188
- Novo Nordisk$116
- Quidel Corporation$84
- plus $314 from 14 others
Across 524 payments — averaging $5969.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$988K
- Bavarian Nordic A/s$518K
- Merck$380K
- Abbott$340K
- Pfizer$319K
- AstraZeneca$238K
- plus $346K from 6 others
What the payments were for
- Consulting fees$1,20047%
- Food & beverage$1,37153%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,230 |
| AbbVie | 17 | $320 |
| AstraZeneca | 14 | $318 |
| Amarin Pharma, Inc. | 8 | $188 |
| Novo Nordisk | 3 | $116 |
| Quidel Corporation | 1 | $84 |
| Amgen(2 entities) | 3 | $62 |
| Exact Sciences | 2 | $35 |
| Edwards Lifesciences | 1 | $30 |
| GSK | 2 | $28 |
| Baxter Healthcare | 1 | $22 |
| Abbott | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Intra-sana Laboratories | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Gilead | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- FARXIGA$110
- Vascepa$109
How this compares
$2,571 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 55 | $39,281 |
| OzempicSemaglutide | 28 | $29,805 |
| EliquisApixaban | 23 | $25,976 |
| JardianceEmpagliflozin | 11 | $16,541 |
| JanuviaSitagliptin Phosphate | 13 | $15,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,811 |
| DapagliflozinDapagliflozin Propanediol | 13 | $10,463 |
| TradjentaLinagliptin | 13 | $8,006 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $6,801 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 121 | $3,442 |
| Ezetimibe | 29 | $2,744 |
| Atorvastatin Calcium | 338 | $2,015 |
| Gabapentin | 129 | $1,899 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $1,617 |
| Levothyroxine Sodium | 144 | $1,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $318 | $39,28155 claims |
| Novo NordiskOzempic | $116 | $29,80528 claims |
| PfizerEliquis | $11 | $25,97623 claims |
| GSKTrelegy Ellipta | $28 | $14,81123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.